< Back to Article

Rhythm profiling using COFE reveals multi-omic circadian rhythms in human cancers in vivo

Fig 4

Rhythmic targets of FDA-approved and clinical candidate cancer drugs.

The -fold amplitude (A) and peak time relative to the core clock (B) of the largest rhythmic target gene in each AC of FDA approved and clinical candidate drugs that target cancer pathways or processes. All FDA-approved drugs and clinical candidates with rhythmic targets in at least 7 ACs are included. Drugs with multiple rhythmic gene targets in an AC are boxed in black. The data underlying Figure panels can be found in S1 Data.

doi: https://doi.org/10.1371/journal.pbio.3003196.g004